Urostad 0.4 mg

Quick links

Choose a section

Quick links to important sections

Advertisements

Urostad 0.4 mg

Advertisements
Advertisements

Treatment option:

Advertisements

Overview of Urostad 0.4 mg

Property Description
Active ingredient Tamsulosin (as Tamsulosin hydrochloride)
Form Modified-release capsule (Oral)
Pharmacological class Alpha-1 adrenergic receptor antagonist
General purpose To decrease muscle tension and resistance to fluid flow
Origin Synthetic, single-ingredient product

Urostad 0.4 mg is a prescription-only therapeutic agent whose medicinal action is derived from its single active ingredient, Tamsulosin (as Tamsulosin hydrochloride). It is classified as an alpha-1 adrenergic receptor antagonist, commonly known as an alpha-blocker. This synthetic compound is manufactured as a modified-release capsule, a specialized solid oral dosage form taken via the oral route of administration. This medicine acts selectively within the alpha1-adrenergic receptor subtype, which provides a key differentiating factor compared to older, non-selective alpha-blockers.

Formulation and Composition

The capsule’s formulation is specifically designed to release the Tamsulosin content gradually and steadily over an extended time frame. This sustained delivery mechanism achieves a consistent systemic level of the active ingredient throughout the day. This controlled profile is a key differentiating feature of the modified-release formulation, which is integral to the product’s identity.

General Therapeutic Purpose

The general therapeutic purpose of Urostad 0.4 mg is to provide smooth muscle relaxation primarily within the lower urinary tract. By selectively blocking the alpha1-adrenergic receptors on these muscular tissues, the medication counteracts the signals that cause tension and constriction. Tamsulosin is used to relax muscles in the prostate and bladder neck. This pharmacological effect reduces muscular tension and resistance, which forms the core principle by which the medication aims to facilitate fluid flow in a typical use scenario involving urinary dynamics.

Regulatory References

  1. Tamsulosin: MedlinePlus Drug Information
  2. Tamsulosin - LiverTox - NCBI Bookshelf
Advertisements

What side effects are possible with Urostad 0.4 mg?

Possible side effects and safety information

The officially documented adverse reactions for Urostad 0.4 mg (Tamsulosin) are classified according to frequency, reflecting data from clinical trials and post-marketing surveillance as documented by government regulatory agencies. The side effects are systematically grouped into System-Organ Classes, primarily involving the Nervous System, Vascular System, and Reproductive System.

Frequency-Classified Adverse Reactions

Frequency Classification Examples of Officially Documented Effects
Very Common (ge 1/10) Dizziness, Abnormal Ejaculation
Common (ge 1/100 to < 1/10) Headache, Rhinitis, Asthenia (weakness)
Uncommon (ge 1/1,000 to < 1/100) Orthostatic Hypotension (dizziness upon standing), Palpitations, Gastrointestinal effects (Nausea, Constipation, Diarrhea), Skin reactions (Rash, Pruritus, Urticaria)
Rare (ge 1/10,000 to < 1/1,000) Syncope (fainting), Angioedema
Very Rare (< 1/10,000) Priapism, Stevens-Johnson Syndrome

Safety Patterns and Constraints

The regulatory safety profile notes that vascular-related effects, such as Orthostatic Hypotension and associated dizziness, are observed more frequently at the beginning of treatment. Similarly, Abnormal Ejaculation is noted to occur upon commencement of treatment.

The medicine is contraindicated in individuals with a known hypersensitivity to the drug or a history of drug-induced Angioedema. Furthermore, the official label specifies a requirement for prostate cancer screening prior to initiating treatment and periodically thereafter, as BPH and prostate carcinoma often co-exist.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information for Urostad 0.4 mg focuses strictly on managing the acute effects of overdosage, which is primarily linked to its pharmacological class.

Documented Manifestations and Severe Outcomes

Overdosage is chiefly associated with severe hypotensive effects and acute hypotension. Other documented manifestations in regulatory reports include symptoms such as vomiting, diarrhoea, headache, dizziness, fainting, and blurred vision. The cardiovascular system is the primary system affected due to the drug’s mechanism.

Required Emergency Actions

Immediate medical attention is required in all cases of suspected overdose. Specific official guidance indicates calling emergency services (e.g., 911) immediately if the individual has collapsed, had a seizure, has trouble breathing, or can't be awakened. Furthermore, individuals should call the poison control helpline for guidance.

Management Procedure Regulatory Recommendation
Cardiovascular Support Positioning the patient lying down to help restore blood pressure; use of volume expanders and, if necessary, vasopressors.
Absorption Impediment Measures like gastric lavage, activated charcoal, or osmotic laxatives may be considered if a large quantity was recently ingested.
Antidote No specific antidote is documented in official labeling.
Dialysis Efficacy Dialysis is considered unlikely to be of help due to high plasma protein binding.
Advertisements

Therapeutic Uses of Urostad 0.4 mg

What Urostad 0.4 mg treats: main uses and benefits

The medication is used in situations involving acute or unstable symptom patterns where additional symptomatic support is needed. It is primarily used for managing symptoms associated with Benign Prostatic Hyperplasia (BPH). This helps manage symptom clusters related to physical discomfort, such as obstructive issues like a weak stream and the sensation of incomplete bladder emptying, as well as irritative symptoms including increased urinary frequency and nocturia.

Urostad 0.4 mg is used across domains where additional symptomatic support is required and is considered relevant for easing symptoms that interfere with daily comfort. This therapeutic use also extends to supportive management in certain urological scenarios, such as assisting with the passage of ureteral stones. This supports the patient during difficult episodes by easing distress and may help in managing symptom fluctuations.

“It helps manage symptoms that interfere with daily comfort, contributing to improved comfort during symptomatic periods.”


Quick Fact: Relief for Obstructive and Irritative LUTS

The medication is relevant for managing symptom clusters that may become intense or disruptive, and contributes to easing the overall symptom load associated with voiding and storage difficulties.

Regulatory References

  1. NIH MedlinePlus overview of Tamsulosin
Advertisements

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Urostad 0.4 mg

The eligibility profile for Urostad 0.4 mg is defined by official regulatory bodies, primarily limiting its use to adult male patients being treated for Benign Prostatic Hyperplasia (BPH). Use in women and children is not indicated as safety and effectiveness have not been established in these populations.

Contraindicated Populations

Urostad 0.4 mg is strictly contraindicated in patients with certain pre-existing conditions:

  • Known hypersensitivity to tamsulosin or any component of the formulation.
  • A documented history of Orthostatic Hypotension (symptoms of low blood pressure upon standing).
  • Severe Hepatic Insufficiency (severe liver impairment).

Use Restrictions and Cautions

Official labeling defines specific restrictions and cautions related to clinical status or planned procedures:

  • Surgical Risk: Initiation of therapy is not recommended for patients scheduled for cataract or glaucoma surgery due to the risk of Intraoperative Floppy Iris Syndrome (IFIS).
  • Renal Impairment: Caution is warranted in patients with Severe Renal Impairment (creatinine clearance less than 10 ml/min), as this patient group has not been adequately studied.
  • Diagnostic Requirement: The possibility of prostate cancer must be excluded prior to starting treatment and during its course, as BPH and prostate cancer may co-exist.
  • Geriatric Use: While generally safe, greater sensitivity in some older individuals cannot be ruled out.
Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of this medication is primarily defined by its metabolism through liver enzymes and its action on blood pressure.

Do Not Combine (Contraindicated):

  • Strong CYP3A4 Inhibitors: Co-administration with strong inhibitors of the CYP3A4 enzyme, such as the antifungal medicine ketoconazole, is not recommended. This combination may significantly increase the concentration of the drug in the body, which could increase related effects.
  • Other Alpha-Adrenergic Blocking Agents: Use with other alpha-blockers is not recommended due to the potential for an additive blood pressure lowering effect, which may lead to symptomatic hypotension.

Use with Caution Combinations:

  • Moderate CYP Inhibitors: Caution is advised when co-administering with moderate inhibitors of CYP3A4 (e.g., erythromycin) and strong or moderate inhibitors of CYP2D6 (e.g., paroxetine). This is especially important for patients known to be CYP2D6 poor metabolizers, as reduced clearance can lead to increased drug exposure.
  • PDE5 Inhibitors: Concomitant use with Phosphodiesterase-5 (PDE5) inhibitors, such as sildenafil or tadalafil, requires caution. Since both classes of medicine are vasodilators, combining them can potentially cause symptomatic hypotension.
  • Other Blood Pressure Lowering Agents: Using this drug with other antihypertensive medicines may increase the risk of low blood pressure and requires careful use.
  • Diclofenac and Warfarin: The anticoagulant warfarin and the non-steroidal anti-inflammatory drug (NSAID) diclofenac are noted as medicines that may interact, necessitating caution and monitoring during co-administration.

Procedural Constraints:

  • Patients undergoing cataract or glaucoma surgery should advise their ophthalmologist of current or prior use of this medication, as Intraoperative Floppy Iris Syndrome (IFIS) has been documented in association with alpha-blockers.
Advertisements

Mechanism of Action

How Urostad 0.4 mg Works

The mechanism of action begins with Tamsulosin acting as a highly selective competitive antagonist of the mathbfalpha1-adrenergic receptors (alpha1-ARs), particularly the mathbfalpha1 A and mathbfalpha1 D subtypes. By physically blocking these receptors, the drug suppresses the effects of the body's natural contracting signal, Norepinephrine, effectively disabling the sympathetic nervous system pathway that initiates smooth muscle contraction.


The blockade of alpha1-ARs interrupts the Gq-protein signaling cascade, thereby preventing the mathbfCa^2+-mediated release necessary for muscle contraction. This molecular cascade leads to relaxation of smooth muscle tone in the prostate, prostatic capsule, and bladder neck. The resulting physiological change is a direct decrease in dynamic urethral resistance, which alters the fluid pressure gradient. Tamsulosin's action is entirely functional, meaning it only modifies the activity and tension of existing muscle tissue (the dynamic component). It engages mechanisms that modulate signal transduction but provides no effect on cell growth or reduction of tissue volume (the static component).

Advertisements

Dosage and Administration Information

The administration of Urostad 0.4 mg (Tamsulosin hydrochloride) is governed by specific instructions ensuring the medicine's consistent delivery. The prescribed route of administration is oral, utilizing the modified-release capsule form.


Official Dosing and Frequency

The standard starting and maintenance dose is 0.4 mg taken once daily. For individuals who do not adequately respond after two to four weeks of use, the dose may be increased to a maximum of 0.8 mg once daily. If therapy is discontinued or interrupted for several days, official instructions require the medicine to be restarted at the initial 0.4 mg once-daily dose.


Administration Conditions

To maintain the intended gradual release profile, the capsule must be swallowed whole with a glass of water and must not be crushed, chewed, or opened. It is an official requirement that the dose be taken approximately one-half hour following the same meal each day to ensure predictable absorption.


Population-Specific Rules

The medicine is not indicated for use in the pediatric population (patients under 18 years of age). Dosage adjustment is generally not necessary for patients with renal impairment (CrCl ge 10 mL/min) or those with mild to moderate hepatic impairment.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Urostad 0.4 mg

Research Evidence for Lower Urinary Tract Symptoms (LUTS) in BPH

Urostad 0.4 mg was evaluated in research exploring the physical discomfort and functional imbalance associated with Lower Urinary Tract Symptoms (LUTS) in men diagnosed with Benign Prostatic Hyperplasia (BPH). The core evidence base primarily consists of short-term, placebo-controlled, randomized controlled trials (RCTs), typically lasting 4 to 13 weeks. Research explored outcomes related to patient-reported symptom scores, such as the International Prostate Symptom Score (IPSS), and objective functional measures, including Maximum Urinary Flow Rate (Qmax). Studies monitored changes in standardized symptom scores and objective urinary flow rates, with findings describing group patterns related to baseline values over the short duration of the trials.

Types of Studies Used for Regulatory Approval

The body of evidence that forms the basis for regulatory review comes from these short-term, placebo-controlled trials. Beyond these, longer-term follow-up is provided by Open-Label Extension Studies (OLEs), which monitor how symptom score patterns evolved in the observed populations for up to several years in patients who continued treatment. However, these extension studies lack a simultaneous, randomized control group for comparison.


Evidence Structure for Use in Ureteral Stone Management

The medicine was also evaluated in studies that explored the supportive management of ureteral stones, particularly small stones in the lower ureter. This evidence consists mainly of Randomized Controlled Trials (RCTs) and Systematic Reviews. Research described patterns related to stone expulsion rates, examined the time to stone expulsion, and monitored outcomes related to physical discomfort by measuring the frequency of pain episodes and analgesic use. It is noted that this use is often considered outside the main approved indication in the official regulatory documents of certain jurisdictions, despite the existing clinical research.


Key Limitations and Unanswered Questions in the Research

The most rigorous, controlled evidence for the patterns observed is limited to short follow-up durations. There is limited information for long-term outcomes regarding the research exploring serious BPH complications, such as the complete inability to pass urine (acute urinary retention) or the need for surgery. For the secondary indication of ureteral stones, evidence quality varies across studies, and findings were mixed, with certainty remaining low regarding its use for larger stones or those located in the upper ureter. In summary, evidence highlights what is known—the short-term, symptom-focused patterns—and what is still uncertain—the long-term impact on disease progression and outcomes.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Urostad 0.4 mg (FAQ)

Q: Does Urostad 0.4 mg help with the passing of kidney stones?

The primary approved purpose of Urostad 0.4 mg is to help relieve the urinary symptoms of an enlarged prostate (BPH). However, clinical research has also explored its role in the supportive management of small ureteral stones. This is a use that is sometimes examined outside of the main regulatory indication.


Q: How quickly should I expect Urostad 0.4 mg to start improving my urinary symptoms?

Studies indicate that patients may begin to see improvements in their urinary symptoms relatively quickly. Symptom relief typically starts within the first four weeks of consistent treatment.


Q: How long does it typically take to feel the full effects of Urostad 0.4 mg?

Clinical data suggests that the full therapeutic effect on urinary flow rate and symptom scores is usually achieved within the first few weeks of consistent, daily use. This timeframe is often used by prescribers to evaluate the medication’s success.


Q: What are the most frequently reported side effects of Urostad 0.4 mg?

According to official regulatory documents, the two most frequently reported side effects are dizziness and a form of ejaculation problem known as abnormal ejaculation.


Q: Is it normal to feel dizzy or light-headed when first starting Urostad 0.4 mg?

Yes, dizziness or light-headedness (Orthostatic Hypotension) is a recognized side effect, particularly when first starting the medication. This effect is a known side effect of the alpha-blocker class of medicine and often occurs when standing up quickly.


Q: Is it possible to experience reduced semen volume while taking this medication?

Yes, it is possible to experience a decrease in the amount of semen or no semen at all. This condition is officially documented as 'Abnormal Ejaculation' and is a commonly reported side effect associated with the medicine.


Q: What are the major warning signs of a serious side effect from Urostad 0.4 mg?

Though rare, serious reactions include a painful erection lasting over two hours (Priapism), fainting (Syncope), or severe swelling of the face, tongue, or throat (Angioedema). Official documentation lists these serious reactions as conditions that require immediate medical attention.


Q: Can Urostad 0.4 mg lead to gastrointestinal issues like diarrhea or constipation?

Gastrointestinal effects such as nausea, constipation, and diarrhea are documented in official safety information. These symptoms are classified as uncommon side effects.


Q: Are tiredness or reduced energy levels associated with taking Urostad 0.4 mg?

Yes, a feeling of weakness or lack of energy, officially termed Asthenia, is listed in the official safety information. This effect is noted as a common side effect of the medicine.


Q: Why is it recommended to take Urostad 0.4 mg after a meal?

Official instructions require the capsule be taken approximately one-half hour following the same meal each day. This specific administration condition is required to ensure consistent and predictable absorption of the drug into the body.


Q: How long after stopping Urostad 0.4 mg will my symptoms potentially return?

Regulatory guidance warns that if the medication is stopped suddenly, the original urinary symptoms may quickly return or worsen. There is no specified timeframe for the return of symptoms, but a prompt return is possible.


Q: Can I take Urostad 0.4 mg if I have pre-existing kidney problems?

Dosage adjustment is generally not required for patients with mild to moderate kidney impairment. However, official guidance advises caution for patients with severe kidney impairment, as studies for this group are limited.


Q: Are there reported interactions between Urostad 0.4 mg and cold or flu medicines?

Caution is advised when combining this medication with over-the-counter cold or flu preparations. Some of these products may contain ingredients that also have alpha-adrenergic blocking or blood pressure-lowering effects, which could lead to additive effects.


Q: How soon do the side effects of Urostad 0.4 mg typically start after the first dose?

Side effects related to low blood pressure, such as dizziness upon standing, are most common during the start of therapy. These initial effects may occur relatively quickly after the first dose, potentially within the first few hours.


Q: Is Urostad 0.4 mg meant for long-term use?

Tamsulosin is commonly used for long-term management to help maintain symptom relief. Official sources indicate the medicine is suitable for continuous, extended use.


Q: Is it safe to consume alcohol while taking Urostad 0.4 mg?

Concomitant consumption of alcohol can increase the potential blood pressure-lowering effects of the medicine. This combination may increase the risk of symptoms like dizziness, light-headedness, or fainting.


Q: Are there any specific foods or drinks, like grapefruit juice, that should be avoided with Urostad 0.4 mg?

Specific drinks like grapefruit juice may increase the concentration of the drug in the body. This increase could potentially elevate the risk of experiencing side effects.


Q: Is it better to take Urostad 0.4 mg in the morning or at night?

The time of day for administration is flexible, whether morning or night. Official guidance emphasizes consistency, stating the dose should be taken approximately one-half hour following the same meal each day.


Q: What happens if I stop taking Urostad 0.4 mg suddenly?

Official guidance warns against stopping the medication suddenly. If the medicine is discontinued, the original urinary symptoms may quickly return or worsen.


Q: Does Urostad 0.4 mg have an impact on blood pressure in general?

While the medication is not indicated for treating high blood pressure, its action as an alpha-blocker can lead to a blood pressure-lowering effect. This is why dizziness upon standing may be experienced.


Q: Can Urostad 0.4 mg be taken by people with a sulfa drug allergy?

Rare instances of allergic reactions have been reported in individuals with a known sulfa drug allergy. Official information states that caution is necessary, particularly if a person has a history of severe or life-threatening reactions to sulfa drugs.


Q: Does Urostad 0.4 mg affect a person's ability to drive or use machinery?

Because dizziness and light-headedness are reported side effects, caution is advised. Official guidance states that activities requiring alertness, such as driving or operating machinery, should be avoided if these symptoms are experienced.


Q: Is it possible for Urostad 0.4 mg to cause body aches or joint pain?

Joint pain and back pain have been reported in official side effect profiles. These musculoskeletal symptoms are listed among the documented side effects of the medication.


Q: Why does taking Urostad 0.4 mg sometimes cause a cough or sore throat?

Cough and sore throat are reported side effects in the official documentation. In rare circumstances, these symptoms may also be related to a potential hypersensitivity reaction.


Q: Can Urostad 0.4 mg be used for conditions other than BPH, such as prostatitis?

While the medicine's main official purpose is for BPH symptoms, it is occasionally taken to address symptoms related to other conditions of the lower urinary tract, such as prostatitis.


Q: Is it true that Urostad 0.4 mg works best when taken for a long period?

Authoritative sources indicate that the sustained effect of the medication is maintained when taken consistently over a long period for the continuous relief of BPH symptoms.


Q: Does Urostad 0.4 mg lower blood pressure enough to be used as a treatment for hypertension?

No, the blood pressure-lowering effect is a known pharmacological action but is not the drug’s intended use. Official guidance specifies that this medication is not indicated or effective for the treatment of high blood pressure (hypertension).


Q: Is it common to still experience night-time urination (nocturia) while on Urostad 0.4 mg?

Clinical studies suggest that tamsulosin may help in improving nocturia (night-time urination) scores in patients with BPH, and may also reduce nighttime urine volume.


Q: Is Urostad 0.4 mg related to any other drugs used for urinary problems?

Urostad 0.4 mg belongs to the alpha-blocker class of drugs. It is sometimes used in combination with other classes of medications for urinary problems, such as those that reduce prostate size or medicines that help control bladder function.


Q: Does Urostad 0.4 mg cause confusion or drowsiness?

Drowsiness (sleepiness) is a documented side effect. Confusion is also noted as a possible symptom that can occur as part of a severe, rare reaction.


Q: Why is my doctor checking my blood pressure regularly while I am taking this medication?

Regular blood pressure monitoring is often done due to the risk of Orthostatic Hypotension (dizziness upon standing). This check helps confirm that the medicine is not causing excessive blood pressure drops, especially when taken alongside other blood pressure-lowering agents.


Q: Is there a difference in how Urostad 0.4 mg is dosed in different countries?

Official starting dose regimens can vary geographically based on regulatory approvals and clinical practice. For instance, the typical starting dose used in some countries may be lower than the standard dose used in others.


Q: Does Urostad 0.4 mg affect the volume of urine produced?

Clinical studies have investigated this question in certain patients. Research suggests that the medicine may help reduce the volume of urine produced during the night in patients with nocturnal polyuria.

Advertisements

How should Urostad 0.4 mg be stored and disposed of?

How to Store and Dispose of Urostad 0.4 mg (Tamsulosin Hydrochloride)

Official regulatory documents define specific conditions for storing and handling Urostad 0.4 mg to ensure product stability and safety.


Storage Requirements

Condition Regulatory Statement
Temperature Store below 25 °C or 30 °C (Controlled Room Temperature).
Protection Keep the medicine in its original package to protect from light.
Child Safety Keep this medicine out of the sight and reach of children.
Handling The modified-release capsule must not be crushed, chewed, or opened.

Disposal Instructions

Official labeling requires that any unused or expired Urostad 0.4 mg must be disposed of in accordance with local requirements. It must not be thrown away via wastewater or household waste to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Urostad 0.4 mg found in:

A-Z Index: